These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27292159)

  • 1. Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
    Gómez-García F; Epstein D; Isla-Tejera B; Lorente A; Vélez García-Nieto A; Ruano J
    Br J Dermatol; 2017 Mar; 176(3):594-603. PubMed ID: 27292159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
    Schmitt J; Rosumeck S; Thomaschewski G; Sporbeck B; Haufe E; Nast A
    Br J Dermatol; 2014 Feb; 170(2):274-303. PubMed ID: 24131260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis.
    Nast A; Jacobs A; Rosumeck S; Werner RN
    J Invest Dermatol; 2015 Nov; 135(11):2641-2648. PubMed ID: 26046458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe and acute complications of biologics in psoriasis.
    Oussedik E; Patel NU; Cash DR; Gupta AS; Feldman SR
    G Ital Dermatol Venereol; 2017 Dec; 152(6):586-596. PubMed ID: 28895664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
    Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
    J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapies for psoriasis: an evidence-based update.
    Sandoval LF; Pierce A; Feldman SR
    Am J Clin Dermatol; 2014 Jul; 15(3):165-80. PubMed ID: 24496885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.
    Jabbar-Lopez ZK; Yiu ZZN; Ward V; Exton LS; Mohd Mustapa MF; Samarasekera E; Burden AD; Murphy R; Owen CM; Parslew R; Venning V; Warren RB; Smith CH
    J Invest Dermatol; 2017 Aug; 137(8):1646-1654. PubMed ID: 28457908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis.
    Erichsen CY; Jensen P; Kofoed K
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):30-38. PubMed ID: 31419343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
    Imafuku S; Nakano A; Dakeshita H; Li J; Betts KA; Guerin A
    J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
    Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
    Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
    Kurzeja M; Rudnicka L; Olszewska M
    Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
    Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
    J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.
    Chen Z; Gong Y; Shi Y
    Clin Drug Investig; 2017 Oct; 37(10):891-899. PubMed ID: 28755058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
    Rustin MH
    Br J Dermatol; 2012 Nov; 167 Suppl 3():3-11. PubMed ID: 23082810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.